Injectable sustained-release formulations for treatment of joint pain and inflammation
Summary
USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.
What changed
USPTO issued patent grant US12589102B2 (Kind B2) to FORDOZ Pharma Corp. on March 31, 2026. The patent covers injectable sustained-release formulations containing both steroidal anti-inflammatory drugs (e.g., A61K 31/573) and non-steroidal anti-inflammatory drugs (e.g., A61K 31/415) loaded into microspheres (A61K 9/5031) for treating joint pain and inflammation caused by rheumatoid arthritis or osteoarthritis. The original application 17606023 was filed on May 6, 2020.
Pharmaceutical manufacturers developing similar sustained-release injectable formulations for arthritis treatment should review this patent to assess freedom-to-operate implications. Healthcare providers administering injectable arthritis treatments should be aware that FORDOZ Pharma now holds IP rights to this specific microsphere-based dual-drug delivery technology. Patent portfolio managers should document this grant and consider whether it affects existing development programs or licensing strategies.
What to do next
- Review patent claims for potential infringement if developing similar injectable sustained-release arthritis formulations
- Update IP portfolio documentation to reflect new competing patent
- Conduct freedom-to-operate analysis if manufacturing or licensing products in this technology space
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Injectable sustained-release formulations for treatment of joint pain and inflammation
Grant US12589102B2 Kind: B2 Mar 31, 2026
Assignee
FORDOZ Pharma Corp.
Inventors
Sydney Ugwu, James He, Zengli Fu
Abstract
Drug-loaded microspheres containing both a steroidal anti-inflammatory drug and a non-steroidal anti-inflammatory drug and injectable formulations containing the microspheres for sustained release of both drugs are disclosed. Methods of making such drug-loaded microspheres, formulations, and use of them for treating pains and inflammations, especially those caused by rheumatoid arthritis or osteoarthritis using such microspheres and formulations are also described.
CPC Classifications
A61K 31/58 A61K 9/0019 A61K 9/1641 A61K 9/1682 A61K 31/415 A61K 9/10 A61K 9/5031 A61K 31/573 A61K 31/635 A61K 47/36 A61K 47/38 A61K 45/06 A61P 19/02
Filing Date
2020-05-06
Application No.
17606023
Claims
9
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.